Clinical trials: Relapsed Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
This open-label, multicenter, three cohorts, phase II study is designed to assess a combination of Zanubrutinib/Venetoclax/Glofitamab or Venetoclax/Glofitamab in high-risk subjects with either first line or R/R Mantle Cell…
- Trial name
- GLOASIS (NCT06558604)
- Testing
- Obinutuzumab, Glofitamab, Venetoclax Oral Product
- Where
- 16 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- The Lymphoma Academic Research Organisation
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
The goal of the clinical research study is to find the highest tolerable dose of nelarabine when given as a continuous infusion to patients with a lymphoid malignancy that has not responded to, or has come back after treatment…
- Trial name
- NCT01094860
- Testing
- Nelarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma, Mantle Cell Lymphoma
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
This is a multicenter, open label, single arm, phase I/II study. There will be no placebo usage within this trial. Phase I: Primary: To establish a maximum tolerated dose of the addition of Temsirolimus to a regimen of…
- Trial name
- BERT (NCT01078142)
- Testing
- Temsirolimus, Rituximab, Bendamustin
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Georg Hess, MD
Follicular Lymphoma, Diffuse Large Cell Lymphoma
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
- Conditions
- Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00275431
- Testing
- AT-101
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascenta Therapeutics
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I trial studies the safety and how effective the combination of ublituximab, umbralisib, and lenalidomide is in certain types of indolent (slow-growing) non-Hodgkin's lymphoma or mantle cell lymphoma.
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04635683
- Testing
- Lenalidomide, Ublituximab, Umbralisib
- Sponsor
- Yazeed Sawalha
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NVG-111 is a bispecific antibody drug, having two "arms", one arm attaches to a substance on cancer cells called ROR1, the other arm attaches to the body's immune cells directing them to kill the cancer cells.
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04763083
- Testing
- NVG-111
- Where
- 3 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- NovalGen Ltd.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Mantle Cell Lymphoma
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose…
- Trial name
- NCT01170052
- Testing
- Temsirolimus, Bendamustine
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Lymphoma, Mantle-Cell
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
- Trial name
- VEGA (NCT05564052)
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 66 sites in Brazil, Czechia and 11 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Burkitt Lymphoma, Lymphoma, Follicular
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
- Conditions
- Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
- Trial name
- NCT01786135
- Testing
- SGN-CD19A
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seagen Inc.
Leukemia, Lymphoma
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00176475
- Testing
- rituximab, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Myeloproliferative Disorders, Leukemia
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00068523
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Mantle Cell Lymphoma
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma
The Primary Objective is to evaluate the safety and tolerability of the DTRMWXHS-12 capsule in patients with relapsed/refractory MCL and recommend the dose and dosing method (RP2D) used in phase II study.
- Trial name
- NCT03836768
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang DTRM Biopharma
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center